<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208181</url>
  </required_header>
  <id_info>
    <org_study_id>0663-107</org_study_id>
    <secondary_id>2010-019871-31</secondary_id>
    <nct_id>NCT01208181</nct_id>
  </id_info>
  <brief_title>A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)</brief_title>
  <official_title>A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MKâ€‘0663/Etoricoxib in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part (6 weeks duration for each part), randomized, double-blind,
      placebo-controlled study in participants with rheumatoid arthritis. The hypothesis is that
      etoricoxib (60 mg and 90 mg) administration will demonstrate superior efficacy compared to
      placebo after 6 weeks of treatment, as measured by the greater mean improvement from baseline
      in the Disease Activity Score C-Reactive Protein (DAS-28 CRP), and by the greater mean
      improvement in Patient Global Assessment of Pain (PGAP) from baseline over 6 weeks of
      treatment. Additionally, the added benefit of increasing the dose of etoricoxib from 60 mg to
      90 mg will be assessed in the second part of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Disease Activity Score Using C-Reactive Protein [DAS28-CRP] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56*square root (sqrt) (tender joint count [28])+0.28*sqrt(swollen joint count [28] )+0.36* ln(crp+1) + 0.014* Patient Global Assessment of Disease Activity + 0.96. The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Adverse Event (AE)</measure>
    <time_frame>Up to 112 days</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Drug Due to an AE</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Disease Activity Score Using C-Reactive Protein [DAS28-CRP] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56*square root (sqrt) (tender joint count [28])+0.28*sqrt(swollen joint count [28] )+0.36* ln(crp+1) + 0.014* Patient Global Assessment of Disease Activity + 0.96. The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1</measure>
    <time_frame>Week 6 and Week 10 to Week 12</time_frame>
    <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). In those participants who were considered inadequate responders to etoricoxib 60 mg in Part 1 (defined as a participant with &lt;50% improvement from baseline in PGAP [VAS] at Week 6), the incremental benefit of increasing the etoricoxib dose from 60 mg (in Part 1) to 90 mg (in Part 2) compared to remaining on 60 mg in Part 2 was evaluated via average change from Week 6 over Weeks 10 and 12 in Patient Global Assessment of Pain score. Therefore, data for only these 2 arms are displayed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1404</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Etoricoxib 60 mg/Etoricoxib 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoricoxib 60 mg/Etoricoxib 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib 60 mg</intervention_name>
    <description>One tablet orally once daily for 6 weeks.</description>
    <arm_group_label>Etoricoxib 60 mg/Etoricoxib 60 mg</arm_group_label>
    <arm_group_label>Etoricoxib 60 mg/Etoricoxib 90 mg</arm_group_label>
    <other_name>MK-0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib 90 mg</intervention_name>
    <description>One tablet orally once daily for 6 weeks.</description>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
    <other_name>MK-0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Etoricoxib 60 mg</intervention_name>
    <description>One tablet orally once daily for 6 weeks.</description>
    <arm_group_label>Etoricoxib 60 mg/Etoricoxib 60 mg</arm_group_label>
    <arm_group_label>Etoricoxib 60 mg/Etoricoxib 90 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Etoricoxib 90 mg</intervention_name>
    <description>One tablet orally once daily for 6 weeks</description>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is male or female â‰¥ 18 years of age in general good health (other than RA)

          -  Has an American College of Rheumatology Rheumatoid Clinical Response Criteria (ACR)
             Functional Class I, II, or III

          -  Has a diagnosis of RA at least 6 months ago and was at least 16 years of age when
             diagnosed

          -  Has a history of positive therapeutic benefit with nonsteroidal anti-inflammatory
             drugs (NSAIDs) and is taking an NSAID on a regular basis and at a therapeutic dose
             level and is not anticipated to undergo a change during the study

        Exclusion Criteria:

          -  Has a concurrent medical/arthritic disease that could confound or interfere with
             evaluation of efficacy

          -  Has a history of gastric or biliary surgery (including gastric bypass surgery) or
             small intestine surgery that causes clinical malabsorption

          -  Has an active peptic (gastric or duodenal) ulcer or history of inflammatory bowel
             disease

          -  Has a confirmed medical diagnosis of ischemic heart disease, cerebrovascular disease,
             or peripheral artery occlusive disease

          -  Class II-IV congestive heart failure

          -  Has uncontrolled hypertension (systolic &gt;160 mm Hg or diastolic &gt; 90 mm Hg) at Visit 1
             or Visit 2

          -  Has a clinical diagnosis of hepatic insufficiency defined as Child-Pugh score â‰¥5

          -  Has estimated glomerular filtration rate â‰¤30 mL/min

          -  Has a history of neoplastic disease within 5 years (exceptions: basal cell carcinoma
             or carcinoma in situ of the cervix)

          -  Is allergic to etoricoxib; history of a significant clinical or laboratory adverse
             experience associated with etoricoxib; hypersensitivity to aspirin or NSAIDs; or
             allergy to acetaminophen/paracetamol

          -  Has a personal or family history of an inherited or acquired bleeding disorder

          -  Requires oral corticosteroid therapy in excess of the equivalent of 10 mg daily of
             prednisone and/or have not been on a stable dose for at least 4 weeks prior to Visit 1
             and/or whose dose is not expected to remain stable during the study

          -  Treated with B-cell depleting therapies within the past 6 months or anticipate this
             treatment during this trial

          -  Is a recreational or illicit drug use, or history within 5 years of drug or alcohol
             abuse/dependence;

          -  Is morbidly obese (defined as body mass index â‰¥40 kg/m^2)

          -  Is pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Bickham K, Kivitz AJ, Mehta A, Frontera N, Shah S, Stryszak P, Popmihajlov Z, Peloso PM. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi: 10.1186/s12891-016-1170-0.</citation>
    <PMID>27502582</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <results_first_submitted>May 5, 2015</results_first_submitted>
  <results_first_submitted_qc>May 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2015</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0663-107&amp;kw=0663-107&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etoricoxib 60 mg</title>
          <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
        </group>
        <group group_id="P2">
          <title>Etoricoxib 90 mg</title>
          <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
        </group>
        <group group_id="P3">
          <title>Etoricoxib 60 mg/Etoricoxib 60 mg</title>
          <description>The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence received etoricoxib tablets 60 mg administered orally once daily in Part 1 and Part 2 of the study.</description>
        </group>
        <group group_id="P4">
          <title>Etoricoxib 60/Etoricoxib 90mg</title>
          <description>The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study and etoricoxib tablets 90 mg administered orally once daily in Part 2 of the study.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>The placebo treatment group received placebo to etoricoxib tablets administered orally once daily in Part 1 of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="818"/>
                <participants group_id="P2" count="468"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="719">Six participants from this arm did not continue into Part II of the study</participants>
                <participants group_id="P2" count="413">Per protocol, participants in this arm did not continue into Part II of the study</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="96">Per protocol, participants in this arm did not continue into Part II of the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problem</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Per protocol, there were no participants in this arm during Part II of the study</participants>
                <participants group_id="P2" count="0">Per protocol, there were no participants in this arm during Part II of the study</participants>
                <participants group_id="P3" count="350">Participants receiving etoricoxib 60 mg in Part I received etoricoxib 60 mg in Part II of the study</participants>
                <participants group_id="P4" count="363">Participants receiving etoricoxib 60 mg in Part I received etoricoxib 90 mg in Part II of the study</participants>
                <participants group_id="P5" count="0">Per protocol, participants did not receive placebo during Part II of the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="334"/>
                <participants group_id="P4" count="343"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etoricoxib 60 mg</title>
          <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
        </group>
        <group group_id="B2">
          <title>Etoricoxib 90 mg</title>
          <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>The placebo treatment group received placebo to etoricoxib tablets administered orally once daily in Part 1 of the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="818"/>
            <count group_id="B2" value="468"/>
            <count group_id="B3" value="118"/>
            <count group_id="B4" value="1404"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="11.9"/>
                    <measurement group_id="B2" value="54.0" spread="12.3"/>
                    <measurement group_id="B3" value="53.6" spread="11.0"/>
                    <measurement group_id="B4" value="53.8" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="677"/>
                    <measurement group_id="B2" value="395"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="1172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score using C reactive protein (DAS28-CRP)</title>
          <description>The DAS28-CRP index (0 - 10 Range) is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56*square root (sqrt) (tender joint count [28])+0.28*sqrt(swollen joint count [28] )+0.36* ln(crp+1) + 0.014* Patient Global Assessment of Disease Activity + 0.96. (N = 732, 426, 103 for Etoricoxib 60 mg, Etoricoxib 90 mg, and Placebo).</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.64" spread="0.99"/>
                    <measurement group_id="B2" value="5.62" spread="1.00"/>
                    <measurement group_id="B3" value="5.65" spread="1.12"/>
                    <measurement group_id="B4" value="5.63" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Global Assessment of Pain</title>
          <description>A participant overall assessment of pain on a visual analog scale (VAS) were assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). (N = 751, 430, 108 for Etoricoxib 60 mg, Etoricoxib 90 mg, and Placebo)</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.84" spread="15.50"/>
                    <measurement group_id="B2" value="70.58" spread="15.02"/>
                    <measurement group_id="B3" value="74.08" spread="14.23"/>
                    <measurement group_id="B4" value="71.02" spread="15.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)</title>
        <description>Disease Activity Score Using C-Reactive Protein [DAS28-CRP] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56*square root (sqrt) (tender joint count [28])+0.28*sqrt(swollen joint count [28] )+0.36* ln(crp+1) + 0.014* Patient Global Assessment of Disease Activity + 0.96. The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>The modified intention-to-treat (mITT) population in Part 1 consisted of all randomized participants receiving at least 1 dose of study medication, had baseline data for the analysis endpoint, and least one post-randomization measurement for the analysis endpoint that was collected within 3 days after the last dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg</title>
            <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg</title>
            <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>The placebo treatment group received placebo to etoricoxib tablets administered orally once daily in Part 1 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)</title>
          <description>Disease Activity Score Using C-Reactive Protein [DAS28-CRP] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56*square root (sqrt) (tender joint count [28])+0.28*sqrt(swollen joint count [28] )+0.36* ln(crp+1) + 0.014* Patient Global Assessment of Disease Activity + 0.96. The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.</description>
          <population>The modified intention-to-treat (mITT) population in Part 1 consisted of all randomized participants receiving at least 1 dose of study medication, had baseline data for the analysis endpoint, and least one post-randomization measurement for the analysis endpoint that was collected within 3 days after the last dose of study medication.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" lower_limit="-1.48" upper_limit="-1.30"/>
                    <measurement group_id="O2" value="-1.37" lower_limit="-1.48" upper_limit="-1.26"/>
                    <measurement group_id="O3" value="-1.10" lower_limit="-1.29" upper_limit="-0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Tukey-Ciminera-Heysetrend test</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Tukey-Ciminera-Heysetrend test</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)</title>
        <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>The mITT population in Part 1 consisted of all randomized participants receiving at least 1 dose of study medication, had baseline data for the analysis endpoint, and least one post-randomization measurement for the analysis endpoint that was collected within 3 days after the last dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg</title>
            <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg</title>
            <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>The placebo treatment group received placebo to etoricoxib tablets administered orally once daily in Part 1 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)</title>
          <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.</description>
          <population>The mITT population in Part 1 consisted of all randomized participants receiving at least 1 dose of study medication, had baseline data for the analysis endpoint, and least one post-randomization measurement for the analysis endpoint that was collected within 3 days after the last dose of study medication.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="751"/>
                <count group_id="O2" value="430"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.25" lower_limit="-30.05" upper_limit="-26.44"/>
                    <measurement group_id="O2" value="-30.96" lower_limit="-33.13" upper_limit="-28.79"/>
                    <measurement group_id="O3" value="-20.26" lower_limit="-24.04" upper_limit="-16.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Tukey-Ciminera-Heyse trend test</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-7.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.85</ci_lower_limit>
            <ci_upper_limit>-4.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Tukey-Ciminera-Heyse trend test</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-10.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.74</ci_lower_limit>
            <ci_upper_limit>-6.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)</title>
        <description>Disease Activity Score Using C-Reactive Protein [DAS28-CRP] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56*square root (sqrt) (tender joint count [28])+0.28*sqrt(swollen joint count [28] )+0.36* ln(crp+1) + 0.014* Patient Global Assessment of Disease Activity + 0.96. The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>The mITT population in Part 1 consisted of all randomized participants receiving at least 1 dose of study medication, had baseline data for the analysis endpoint, and least one post-randomization measurement for the analysis endpoint that was collected within 3 days after the last dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg</title>
            <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg</title>
            <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)</title>
          <description>Disease Activity Score Using C-Reactive Protein [DAS28-CRP] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56*square root (sqrt) (tender joint count [28])+0.28*sqrt(swollen joint count [28] )+0.36* ln(crp+1) + 0.014* Patient Global Assessment of Disease Activity + 0.96. The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.</description>
          <population>The mITT population in Part 1 consisted of all randomized participants receiving at least 1 dose of study medication, had baseline data for the analysis endpoint, and least one post-randomization measurement for the analysis endpoint that was collected within 3 days after the last dose of study medication.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="732"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" lower_limit="-1.48" upper_limit="-1.30"/>
                    <measurement group_id="O2" value="-1.37" lower_limit="-1.48" upper_limit="-1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.730</p_value>
            <method>Tukey-Ciminera-Heysetrend test</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)</title>
        <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>The mITT population in Part 1 consisted of all randomized participants receiving at least 1 dose of study medication, had baseline data for the analysis endpoint, and least one post-randomization measurement for the analysis endpoint that was collected within 3 days after the last dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg</title>
            <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg</title>
            <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)</title>
          <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.</description>
          <population>The mITT population in Part 1 consisted of all randomized participants receiving at least 1 dose of study medication, had baseline data for the analysis endpoint, and least one post-randomization measurement for the analysis endpoint that was collected within 3 days after the last dose of study medication.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="751"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.25" lower_limit="-30.05" upper_limit="-26.44"/>
                    <measurement group_id="O2" value="-30.96" lower_limit="-33.13" upper_limit="-28.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Tukey-Ciminera-Heyse trend test</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>-2.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.98</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1</title>
        <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). In those participants who were considered inadequate responders to etoricoxib 60 mg in Part 1 (defined as a participant with &lt;50% improvement from baseline in PGAP [VAS] at Week 6), the incremental benefit of increasing the etoricoxib dose from 60 mg (in Part 1) to 90 mg (in Part 2) compared to remaining on 60 mg in Part 2 was evaluated via average change from Week 6 over Weeks 10 and 12 in Patient Global Assessment of Pain score. Therefore, data for only these 2 arms are displayed.</description>
        <time_frame>Week 6 and Week 10 to Week 12</time_frame>
        <population>This population (a subpopulation of the mITT population) was composed of pain inadequate responder (PIRs) in Part 1. PIRs were defined as participants with &lt;50% improvement from baseline in Patient Global Assessment of Pain (VAS) at Week 6 and received at least one dose of study medication in Part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg/Etoricoxib 60 mg</title>
            <description>The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily in Part 1 and Part 2 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 60 mg/Etoricoxib 90 mg</title>
            <description>The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily in Part 1 and etoricoxib 90 mg tablets Part 2 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1</title>
          <description>A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker &quot;no pain&quot; (0 mm) or right-hand marker &quot;extreme pain&quot; (100 mm). In those participants who were considered inadequate responders to etoricoxib 60 mg in Part 1 (defined as a participant with &lt;50% improvement from baseline in PGAP [VAS] at Week 6), the incremental benefit of increasing the etoricoxib dose from 60 mg (in Part 1) to 90 mg (in Part 2) compared to remaining on 60 mg in Part 2 was evaluated via average change from Week 6 over Weeks 10 and 12 in Patient Global Assessment of Pain score. Therefore, data for only these 2 arms are displayed.</description>
          <population>This population (a subpopulation of the mITT population) was composed of pain inadequate responder (PIRs) in Part 1. PIRs were defined as participants with &lt;50% improvement from baseline in Patient Global Assessment of Pain (VAS) at Week 6 and received at least one dose of study medication in Part 2.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.96" lower_limit="-14.96" upper_limit="-8.97"/>
                    <measurement group_id="O2" value="-10.35" lower_limit="-13.32" upper_limit="-7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.327</p_value>
            <method>covariance model</method>
            <param_type>Difference in the least squares mean</param_type>
            <param_value>1.61</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>3.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced at Least One Adverse Event (AE)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
        <time_frame>Up to 112 days</time_frame>
        <population>All Subjects as Treated (ASaT) population, defined as all randomized participants who received at least one study drug. Participants were included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data using the ASaT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg - Part 1</title>
            <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg - Part 1</title>
            <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2</title>
            <description>The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib tablets 60 mg administered orally once daily in Part 1 and Part 2 of the study.</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2</title>
            <description>The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study and etoricoxib tablets 90 mg administered orally once daily in Part 2 of the study.</description>
          </group>
          <group group_id="O5">
            <title>Placebo - Part 1</title>
            <description>The placebo treatment group received placebo to etoricoxib tablets administered orally once daily in Part 1 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least One Adverse Event (AE)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
          <population>All Subjects as Treated (ASaT) population, defined as all randomized participants who received at least one study drug. Participants were included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data using the ASaT population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="819"/>
                <count group_id="O2" value="467"/>
                <count group_id="O3" value="350"/>
                <count group_id="O4" value="363"/>
                <count group_id="O5" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3"/>
                    <measurement group_id="O2" value="36.0"/>
                    <measurement group_id="O3" value="19.1"/>
                    <measurement group_id="O4" value="24.5"/>
                    <measurement group_id="O5" value="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Drug Due to an AE</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>ASaT population defined as all randomized participants who received at least one study drug. Participants were included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data using the ASaT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg - Part 1</title>
            <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg - Part 1</title>
            <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
          </group>
          <group group_id="O3">
            <title>Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2</title>
            <description>The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib tablets 60 mg administered orally once daily in Part 1 and Part 2 of the study.</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2</title>
            <description>The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study and etoricoxib tablets 90 mg administered orally once daily in Part 2 of the study.</description>
          </group>
          <group group_id="O5">
            <title>Placebo - Part 1</title>
            <description>The placebo treatment group received placebo to etoricoxib tablets administered orally once daily in Part 1 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Drug Due to an AE</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.</description>
          <population>ASaT population defined as all randomized participants who received at least one study drug. Participants were included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data using the ASaT population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="819"/>
                <count group_id="O2" value="467"/>
                <count group_id="O3" value="350"/>
                <count group_id="O4" value="363"/>
                <count group_id="O5" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 112 days</time_frame>
      <desc>The All Participants as Treated (APaT) population was used for the analysis of safety data in this study and consisted of all randomized participants who received at least one dose of study treatment. Participants were included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Etoricoxib 60 mg - Part 1</title>
          <description>The etoricoxib 60 mg treatment group received etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study.</description>
        </group>
        <group group_id="E2">
          <title>Etoricoxib 90 mg - Part 1</title>
          <description>The etoricoxib 90 mg treatment sequence received etoricoxib tablets 90 mg administered orally once daily in Part 1 of the study.</description>
        </group>
        <group group_id="E3">
          <title>Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2</title>
          <description>The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib tablets 60 mg administered orally once daily in Part 1 and Part 2 of the study.</description>
        </group>
        <group group_id="E4">
          <title>Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2</title>
          <description>The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib tablets 60 mg administered orally once daily in Part 1 of the study and etoricoxib tablets 90 mg administered orally once daily in Part 2 of the study.</description>
        </group>
        <group group_id="E5">
          <title>Placebo - Part 1</title>
          <description>The placebo treatment group received placebo to etoricoxib tablets administered orally once daily in Part 1 of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="467"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="363"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="819"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="819"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="467"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="350"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="363"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="819"/>
                <counts group_id="E2" events="27" subjects_affected="17" subjects_at_risk="467"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="350"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="363"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

